Phase 2 dose multi-center, open-label study of ARQ 501, a checkpoint activator, in adult patients with persistent, recurrent or metastatic leiomyosarcoma (LMS) We report on 15 patients who were ...
Please provide your email address to receive an email when new articles are posted on . Five-year local recurrence rates were 10% and 17% for atypical fibroxanthoma and pleomorphic dermal sarcoma, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results